Pneumologia e Terapia Intensiva Respiratoria, Dipartimento Cardio-Toraco-Vascolare, Policlinico Sant' Orsola-Malpighi, Bologna, Italy.
Respir Care. 2011 Oct;56(10):1583-8. doi: 10.4187/respcare.01209.
Few studies have been performed on noninvasive ventilation (NIV) to treat hypoxic acute respiratory failure in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). The outcomes of these patients, for whom endotracheal intubation is not mandatory, depend on the degree of hypoxia, the presence of comorbidities and complications, and their illness severity. The use of NIV as an alternative to invasive ventilation in severely hypoxemic patients with ARDS (ie, P(aO(2))/F(IO(2)) < 200) is not generally advisable and should be limited to hemodynamically stable patients who can be closely monitored in an intensive care unit by highly skilled staff. Early NIV application may be extremely helpful in immunocompromised patients with pulmonary infiltrates, in whom intubation dramatically increases the risk of infection, pneumonia, and death. The use of NIV in patients with severe acute respiratory syndrome and other airborne diseases has generated debate, despite encouraging clinical results, mainly because of safety issues. Overall, the high rate of NIV failure suggests a cautious approach to NIV use in patients with ALI/ARDS, including early initiation, intensive monitoring, and prompt intubation if signs of NIV failure emerge.
目前针对肺损伤(ALI)或急性呼吸窘迫综合征(ARDS)患者的低氧性急性呼吸衰竭应用无创通气(NIV)的研究较少。这些患者的结局取决于缺氧程度、合并症和并发症以及疾病严重程度。对于严重低氧血症的 ARDS 患者(即,P(aO(2))/F(IO(2))<200),NIV 替代有创通气通常并不合适,并且应仅限于血流动力学稳定且能够在重症监护病房由高技能人员密切监测的患者。对于肺部浸润的免疫功能低下患者,早期应用 NIV 可能极有帮助,因为气管插管会显著增加感染、肺炎和死亡的风险。尽管有令人鼓舞的临床结果,但 NIV 在严重急性呼吸综合征和其他空气传播疾病患者中的应用仍存在争议,主要是出于安全性问题。总体而言,NIV 失败率较高表明在 ALI/ARDS 患者中应用 NIV 时应谨慎,包括早期启动、强化监测以及如果出现 NIV 失败迹象时及时插管。